Randomized trial · people

Dulaglutide lowered major cardiovascular events (HR 0.88) in REWIND

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large, long trial of older adults with type 2 diabetes, dulaglutide led to fewer major cardiovascular events than placebo, but gut side effects were more common and overall deaths did not clearly differ.

Kind
Randomized trial
Studied in
People
Number studied
9901
Published
2019
Journal
Lancet

What they tested

Does adding weekly dulaglutide to usual diabetes treatment lower the rate of heart attacks, strokes and cardiovascular deaths in people with type 2 diabetes?

How the study was done

A randomized, double-blind, placebo-controlled trial in 9901 adults aged at least 50 with type 2 diabetes who had either a past cardiovascular event or cardiovascular risk factors, run at 371 sites in 24 countries. Participants got a weekly injection under the skin of dulaglutide 1.5 mg or placebo (a dummy shot) and were followed for a median of 5.4 years.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

The main outcome was a first non-fatal heart attack, non-fatal stroke or death from cardiovascular causes. It happened in 594 people (12.0%) on dulaglutide versus 663 (13.4%) on placebo, or 2.4 versus 2.7 per 100 person-years, giving a hazard ratio (a measure of relative risk over time) of 0.88 (95% CI 0.79-0.99). Death from any cause did not clearly differ: 536 (10.8%) versus 592 (12.0%), hazard ratio 0.90 (95% CI 0.80-1.01). Gut side effects were more common on dulaglutide, reported by 2347 people (47.4%) versus 1687 (34.1%) on placebo.

What it doesn’t show

Only one dose, 1.5 mg weekly, was tested, and only in people aged 50 or older with type 2 diabetes and cardiovascular disease or risk factors. The trial was funded by Eli Lilly and Company.

The paper

Gerstein et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019.

The compound

More studies on Dulaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo